Reconstituted high-density lipoprotein nanoparticles comprising cholesterol

Reconstituted high-density lipoprotein nanoparticles with cholesterol and apolipoprotein E3 provide a targeted delivery mechanism across the blood-brain barrier, addressing the limitations of current cancer treatments by inducing cholesterol efflux and cancer cell death, and showing potential for Alzheimer's disease management.

WO2024228596A1PCT designated stage expired Publication Date: 2024-11-07MEPSGEN CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006052
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-03
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current treatments for glioblastoma and pancreatic cancer face challenges due to the blood-brain barrier's limited permeability, leading to ineffective drug delivery and poor prognosis, while Alzheimer's disease also requires improved methods for targeting brain cholesterol metabolism.

Method used

Development of reconstituted high-density lipoprotein (rHDL) nanoparticles containing cholesterol and apolipoprotein E3, which can cross the blood-brain barrier and induce cholesterol efflux from cancer cells, utilizing the LDLR pathway for targeted delivery of 24-hydroxycholesterol to modulate cholesterol metabolism and induce cancer cell death.

Benefits of technology

The rHDL nanoparticles effectively penetrate the blood-brain barrier, increase ABCA1 expression, enhance cholesterol efflux, and induce cancer cell death, offering a promising approach for treating glioblastoma, pancreatic cancer, and potentially Alzheimer's disease with minimal toxicity to normal brain cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006052_07112024_PF_FP_ABST
    Figure KR2024006052_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell inflow rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Reconstituted high-density lipoprotein nanoparticles containing cholesterol

[0001] The present invention relates to reconstituted high density lipoprotein (rHDL) nanoparticles containing cholesterol and a composition for preventing and treating Alzheimer's disease or cancer comprising the same.

[0002] Specifically, the present invention relates to rHDL nanoparticles comprising cholesterol, phospholipid, and apolipoprotein, wherein the rHDL nanoparticles of the present invention have a cancer cell killing effect by promoting cholesterol efflux from cells.

[0003]

[0004] According to global cancer statistics, 19.3 million new cancer cases and 10 million deaths occurred in 2020. Research into the treatment of cancer, the leading cause of death in modern society, is essential. Representative cancer treatments include surgery, biotherapy, radiotherapy, chemotherapy with anticancer agents, and targeted therapy. However, due to side effects that can damage normal organs and negatively impact quality of life, research into more effective anticancer therapies continues. Among these, glioblastoma (GBM) is the most common and aggressive primary brain tumor and one of the deadliest forms of cancer. The current standard of care (SOC) for GBM is the Stupp protocol, which consists of localized radiotherapy, surgical resection, and temozolomide. However, complete surgical resection is impossible due to the delicate anatomy of the brain and the highly invasive nature of GBM. Furthermore, the poor blood-brain barrier (BBB) ​​penetration of existing chemotherapeutic agents, such as temozolomide, makes it difficult to effectively treat GBM. Despite recent advances in surgery, chemotherapy, and immunotherapy, the survival rate for patients diagnosed with GBM is less than two years. Developing alternative and targeted delivery approaches to effectively treat GBM is a pressing challenge in GBM treatment. Understanding the biology of GBM is also crucial for finding new treatments.

[0005] Pancreatic cancer is another challenging malignancy with a poor prognosis, with a median 5-year survival rate of ~5-10%. Factors contributing to its poor prognosis include challenges with early diagnosis, treatment refractoryness, and a hostile tumor microenvironment that promotes rapid evolution of resistance mechanisms. Transcriptome analysis reveals that pancreatic ductal adenocarcinoma (PDAC) is enriched for lipid metabolism pathways compared to normal cells, particularly cholesterol uptake, including expression of the low-density lipoprotein receptor (LDLR) (Raimund O, Life Sci Alliance, 2022) (Fabienne G, PNAS, 2015).

[0006] Cholesterol is a vital nutrient for normal cellular function and survival. It plays a crucial role in the plasma membrane and lipid rafts, and is a precursor to steroid hormones, bile acids, and vitamin D. Because too much or too little intracellular cholesterol can be toxic, cells regulate intracellular cholesterol homeostasis through cholesterol uptake, efflux, and endogenous synthesis. Cells maintain homeostasis by regulating cholesterol biosynthesis and elimination and maintaining consistent and appropriate levels of cholesterol. Cholesterol metabolism is regulated by the coordinated action of the sterol regulatory element-binding protein (SREBP) and liver X receptor (LXR) transcription factors. SREBP enhances cholesterol uptake by inducing cholesterol biosynthetic genes and the low-density lipoprotein receptor (LDLR). LXR not only induces excessive cholesterol efflux by activating cholesterol efflux genes (ABCA1, ABCG1) but also downregulates cholesterol uptake by inducing the synthesis of IDOL (LDLR-inducible degrader), an E3 ubiquitin ligase that mediates LDLR degradation.

[0007] However, a common feature of various cancers is dysregulation of cholesterol homeostasis. Abnormally high cholesterol levels in many cancers, including liver, stomach, colon, pancreatic, and prostate cancers, affect cancer cell proliferation, metastasis, and invasion. GBM, in particular, relies on exogenous cholesterol uptake due to upregulation of LDLR, and inhibits cholesterol efflux due to low cholesterol metabolism and metabolites, leading to excessive intracellular cholesterol accumulation (Leila Pirmoradi, J. Investig. Med., 2019). Excess intracellular cholesterol can be removed by the brain-specific protein cholesterol 24-hydroxylase (CYP46A1) to convert it to oxysterols or 24S-hydroxycholesterol (24HC). However, GBM have lower levels of CYP46A1 expression compared to normal human astrocytes, resulting in a reduced ability to convert cholesterol to 24HC (Mingzhi Han, EMBO Mol. Med., 2020).

[0008] Several endogenous oxysterols, such as 22HC, 25HC, 27HC, and 24HC, are LXR agonists that potently induce LXR transcription. 24HC downregulates ABCA1 in GBM, thereby arresting cell growth and ultimately leading to apoptosis (Sigrid Nachterhaele, Nat. Chem. Biol., 2012). While novel cancer therapeutic approaches targeting pathways involved in cholesterol homeostasis are being explored, the limited permeability of the blood-brain barrier (BBB) ​​makes targeted delivery of LXR agonists to GBM challenging. Therefore, developing delivery systems that target GBM and effectively cross the BBB to deliver sufficient therapeutics is crucial.

[0009] While increased ABCA1 levels may contribute to cancer cell death by increasing intracellular cholesterol efflux, increased ABCA1 expression has also been associated with improved Alzheimer's disease (AD) outcomes. In the brain, ABCA1 can lipidate apolipoprotein E, promote the clearance of amyloid-β (Aβ), and participate in BBB maintenance through apolipoprotein E-mediated pathways. Increased ABCA1 expression may positively influence apolipoprotein E lipidation, insulin sensitivity, peripheral vascular and BBB integrity, and anti-inflammatory signaling. Conversely, decreased ABCA1 levels are associated with decreased apolipoprotein E levels in cerebrospinal fluid and plasma and increased brain amyloid burden, while decreased apolipoprotein E levels are associated with BBB disruption (Radosveta Koldamova, J Biol Chem., 2005). Therefore, the formulation related to ABCA1 increase may be a positive factor not only in anticancer treatment but also in Alzheimer's disease.

[0010] It has been reported that treatment of PDAC cells with the LXR agonist T0901317 increased the expression of the ABCA1 protein, which induces cholesterol efflux, resulting in cancer cell death (Raimund O, Life Sci Alliance, 2022). Therefore, inducing cancer cell death by delivering LXR agonists intracellularly via overexpressed LDLR could be a promising approach for pancreatic cancer treatment.

[0011] High-density lipoprotein (HDL) is a natural nanoparticle composed of apolipoprotein and lipids capable of transporting cholesterol. Based on research demonstrating that HDL and reconstituted high-density lipoprotein (rHDL) can deliver drugs across the blood-brain barrier (BBB), we developed ApoE3-based rHDL nanoparticles containing 24HC, which possesses LDLR binding capacity.

[0012] The present invention has been completed by confirming that rHDL nanoparticles centered on apolipoprotein E3 are nanoparticles containing 24HC, and have an excellent effect in treating tumors through cholesterol control.

[0013] [Prior Art Literature]

[0014] [Non-patent literature]

[0015] (Non-patent document 0001) Leila Pirmoradi, Nayer Seyfizadeh, Saeid Ghavami, Amir A Zeki, Shahla Shojaei, Targeting cholesterol metabolism in glioblastoma: a new therapeutic approach in cancer therapy, J. Investig. Med. 2019 67(4):715-719.

[0016] (Non-patent Document 0002) Mingzhi Han, Shuai Wang, Ning Yang, Xu Wang, Wenbo Zhao, Halala Sdik Saed, Thomas Daubon, Bin Huang, Anjing Chen, Gang Li, Hrvoje Miletic, Frits Thorsen, Rolf Bjerkvig, Xingang Li, Jian Wang, Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma, EMBO Mol. Med. 2020 Jan 9;12(1):e10924.

[0017] (비특허문헌 0003) Sigrid Nachtergaele, Laurel K Mydock, Kathiresan Krishnan, Jayan Rammohan, Paul H Schlesinger, Douglas F Covey, Rajat Rohatgi, Oxysterols are allosteric activators of the oncoprotein smoothened, Nat. Chem. Biol. 2012 Jan 8;8(2):211-220.

[0018] (비특허문헌 0004) Radosveta Koldamova, Matthias Staufenbiel, Iliya Lefterov, Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice, J Biol Chem., 2005 Dec 30;280(52):43224-43235.

[0019] (비특허문헌 0005) Raimund Oberle, Kristina Kuhrer, et al. The HDL particle composition determines its antitumor activity in pancreatic cancer, Life Sci Alliance. 2022 May 16;5(9):e202101317.

[0020] (비특허문선 0006) Fabienne Guillaumond, Ghislain Bidaut, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma, PNAS. 2015 Feb 124;112(8):2473-8.

[0021]

[0022] The present invention aims to provide reconstructed high-density lipoprotein nanoparticles containing cholesterol.

[0023] The present invention aims to provide a composition for preventing or treating Alzheimer's disease or cancer, comprising reconstructed high-density lipoprotein nanoparticles containing cholesterol.

[0024] The present invention aims to provide a method for producing reconstituted high-density lipoprotein nanoparticles containing cholesterol.

[0025] The present invention provides reconstituted high-density lipoprotein (rHDL) nanoparticles comprising phospholipids, cholesterol, and apolipoprotein E.

[0026] The above cholesterol is cholesterol, 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 4β-hydroxycholesterol, α-5,6-epoxycholesterol, β-5,6-epoxycholesterol, 24S, 25-epoxycholesterol, 25-epoxycholesterol, 7-hydroxycholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(R)-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 5β-epoxycholesterol, 6β-epoxycholesterol, 7-dehydrocholesterol, (25R)26-hydroxycholesterol, 7α,(25R)26-dihydroxycholesterol, 5β-cholestane-3α,7α,12α,(25R)26-tetrol, 7α,25-dihydroxycholesterol, 7α,24S-dihydroxycholesterol (7α,24S-dihydroxycholesterol), 3β,5α,6β-cholestane-3,5,6,26-tetrol, Lanosterol, Desmosterol, 7α-hydroxydesmosterol, (24Z),26S-hydroxydesmosterol, (24E),26S-hydroxydesmosterol, 24S,25-epoxylanosterol, 26(Z)-hydroxydesmosterol, 25-hydroxy-8-dehydrocholesterol, 24-hydroxy-8-dehydrocholesterol, 7-dehydrocholesterol, 8-dehydrocholesterol, (25R)26-hydroxy-8-dehydrocholesterol, 25-hydroxy-7-dehydrocholesterol, 4α-hydroxy-7-dehydrocholesterol, 4β-hydroxy-7-dehydrocholesterol, 7,8-epoxycholesterol, 3α,5β,6α-cholestane-3,6-diol, cholestan-3β, 5α, 6β-triol, Oxy34, Oxy49,and may be at least one selected from the group consisting of Oxy133, but is not limited thereto.

[0027] In one embodiment, the cholesterol may be 24-hydroxycholesterol (24HC).

[0028] In one embodiment, the nanoparticles of the present invention may further comprise a liver X receptor (LXR) agonist.

[0029] In one embodiment, the LXR promoter may be one or more selected from the group consisting of, but not limited to, T0901317, GW3965, GW6340, DMHCA, LXR-623, WYE-672, and AZ876.

[0030] When synthesizing the above reconstituted high-density lipoprotein (rHDL) nanoparticles, the synthetic mixing weight ratio of apolipoprotein E and cholesterol may be 1:2 to 1:4, and preferably 1:3.

[0031] In one embodiment, the apolipoprotein E can be apolipoprotein E2, E3, or E2 and E3.

[0032] In one embodiment, the reconstituted high-density lipoprotein (rHDL) nanoparticles may further comprise apolipoprotein A1.

[0033] In one embodiment, the phospholipid is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), 1,2-Diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1,2-Diicosanoyl-sn-glycero-3-phosphocholine (DEPC), Palmitoyloleoylphosphatidylcholine (POPC), Lysophosphatidylcholine, Dilinoleoylphosphatidylcholine, Distearoylphosphatidylethanolamine (DSPE), Dimyristoylphosphatidylethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), Palmitoyloleoylphosphatidylethanolamine (POPE), Lysophosphatidylethanolamine, N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide)(VL-5), Dioctadecylamidoglyclespermine 4-trifluoroacetic acid (DOGS), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), (1,2-dioleyloxypropyl)-3-dimethylhydroxyethyl ammonium bromide (DORIE), 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N-(3-aminopropyl)-N,N-dimethyl-2,One or more selected from the group consisting of 3-bis(dodecyloxy)-1-propanammonium bromide (GAP-DLRIE), Nt-butyl-N'-tetradecyl-3-tetradecylaminopropionamidine (diC14-amidine), ethylphosphocholine (Ethyl PC), dimethyldioctadecylammonium bromide (DDAB), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), D-Lin-MC3-DMA (MC3, DLin-MC3-DMA), DLin-KC2-DMA, and DLin-DMA, but is not limited thereto.

[0034] In one embodiment, the reconstituted high-density lipoprotein (rHDL) nanoparticles may have a diameter of 25 nm or less.

[0035] In one embodiment, the reconstituted high-density lipoprotein (rHDL) nanoparticles can increase the expression of ABCA1.

[0036] In one embodiment, the reconstituted high-density lipoprotein (rHDL) nanoparticles can increase cholesterol efflux.

[0037] In one embodiment, the reconstituted high-density lipoprotein (rHDL) nanoparticles can kill cancer cells.

[0038] In one embodiment, the reconstituted high-density lipoprotein (rHDL) nanoparticles can enter cells via LDLR.

[0039] The present invention provides a composition for preventing or treating Alzheimer's disease or cancer comprising the reconstituted high-density lipoprotein (rHDL) nanoparticles.

[0040] The present invention provides a use of a composition for preventing or treating Alzheimer's disease or cancer comprising the reconstituted high-density lipoprotein (rHDL) nanoparticles.

[0041] The present invention provides a method for treating Alzheimer's disease or cancer by administering the reconstituted high-density lipoprotein (rHDL) nanoparticles to a subject.

[0042] The cancer may be at least one selected from the group consisting of carcinoma, sarcoma, lymphoma, leukemia, germ cell tumor, brain tumor corresponding to blastoma, cervical cancer, ovarian cancer, prostate cancer, lung cancer, bile duct cancer, kidney cancer, stomach cancer, liver cancer, retinoblastoma, choriocarcinoma, small intestine cancer, colon cancer and rectal cancer, non-small cell lung cancer, gastric adenocarcinoma, acute lymphoblastic leukemia, acute myeloid leukemia, breast cancer, bone sarcoma, bladder cancer, anaplastic astrocytoma, head and neck cancer, pancreatic cancer and esophageal cancer, but is not limited thereto, and preferably may be a brain tumor.

[0043] The present invention provides a method for producing cholesterol-containing rHDL nanoparticles, comprising: a first step of injecting a phospholipid solution into a second inlet located in the center of a microfluidic device including three inlets and one outlet; a second step of injecting an apolipoprotein solution into the first and third inlets located on both sides to produce rHDL nanoparticles containing phospholipids and apolipoprotein E; and a third step of dripping cholesterol onto the rHDL nanoparticles.

[0044] In one embodiment, the microfluidic device may include micropillars.

[0045] In one embodiment, the manufacturing method may further include a step of removing the organic solvent after the second step.

[0046] In one embodiment, the cholesterol of the above manufacturing method is cholesterol, 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 4β-hydroxycholesterol, α-5,6-epoxycholesterol, β-5,6-epoxycholesterol, 24S, 25-epoxycholesterol, 25-epoxycholesterol, 7-hydroxycholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(R)-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 5β-epoxycholesterol, 6β-epoxycholesterol, 7-dehydrocholesterol, (25R)26-hydroxycholesterol, 7α,(25R)26-dihydroxycholesterol, 5β-cholestane-3α,7α,12α,(25R)26-tetrol, 7α,25-dihydroxycholesterol (7α,25-dihydroxycholesterol), 7α,24S-dihydroxycholesterol, 3β,5α,6β-cholestane-3,5,6,26-tetrol, Lanosterol, Desmosterol, 7α-hydroxydesmosterol, (24Z),26S-hydroxydesmosterol, (24E),26S-hydroxydesmosterol, 24S,25-epoxylanosterol, 26(Z)-hydroxydesmosterol, 25-hydroxy-8-dehydrocholesterol, 24-hydroxy-8-dehydrocholesterol, 7-dehydrocholesterol, 8-dehydrocholesterol, (25R)26-hydroxy-8-dehydrocholesterol, 25-hydroxy-7-dehydrocholesterol, 4α-hydroxy-7-dehydrocholesterol, 4β-hydroxy-7-dehydrocholesterol, 7,8-epoxycholesterol, 3α,5β,6α-cholestane-3,6-diol, cholestan-3β, 5α, 6β-triol, Oxy34, Oxy49,and may be at least one selected from the group consisting of Oxy133, but is not limited thereto.

[0047] In one embodiment, the cholesterol may be 24-hydroxycholesterol (24HC).

[0048] In one embodiment, the apolipoprotein may be apolipoprotein E.

[0049] In one embodiment, the apolipoprotein E can be apolipoprotein E2, E3, or E2 and E3.

[0050] In one embodiment, the phospholipid is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), 1,2-Diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1,2-Diicosanoyl-sn-glycero-3-phosphocholine (DEPC), Palmitoyloleoylphosphatidylcholine (POPC), Lysophosphatidylcholine, Dilinoleoylphosphatidylcholine, Distearoylphosphatidylethanolamine (DSPE), Dimyristoylphosphatidylethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), Palmitoyloleoylphosphatidylethanolamine (POPE), Lysophosphatidylethanolamine, N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide)(VL-5), Dioctadecylamidoglyclespermine 4-trifluoroacetic acid (DOGS), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), (1,2-dioleyloxypropyl)-3-dimethylhydroxyethyl ammonium bromide (DORIE), 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N-(3-aminopropyl)-N,N-dimethyl-2,One or more selected from the group consisting of 3-bis(dodecyloxy)-1-propanammonium bromide (GAP-DLRIE), Nt-butyl-N'-tetradecyl-3-tetradecylaminopropionamidine (diC14-amidine), ethylphosphocholine (Ethyl PC), dimethyldioctadecylammonium bromide (DDAB), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), D-Lin-MC3-DMA (MC3, DLin-MC3-DMA), DLin-KC2-DMA, and DLin-DMA, but is not limited thereto.

[0051] The cholesterol-containing rHDL nanoparticles of the present invention have cancer treatment and prevention effects. In particular, they can be applied to cancers in which LDLR is overexpressed, such as pancreatic cancer, head and neck cancer, esophageal cancer, gastric cancer, and brain tumors, and are particularly effective for brain tumors. Furthermore, they can cross the blood-brain barrier (BBB) ​​and be used in the treatment and prevention of Alzheimer's disease.

[0052] The cholesterol-containing rHDL nanoparticles of the present invention have the effect of targeting LDLR of glioblastoma and releasing cholesterol from within glioblastoma.

[0053] The cholesterol-containing rHDL nanoparticles of the present invention have a cell death effect by cholesterol efflux from glioblastoma cells.

[0054] The cholesterol-containing rHDL nanoparticles of the present invention can treat glioblastoma by passing through the BBB without toxic effects on BBB constituent cells.

[0055] Therefore, the cholesterol-containing rHDL nanoparticles of the present invention can be used for the treatment of brain tumors and Alzheimer's disease.

[0056] Furthermore, since the rHDL nanoparticles of the present invention can be manufactured using a microfluidic device, mass production of nanoparticles with consistent characteristics (no batch-to-batch variability) is possible. Compared to conventional rHDL, they do not contain additional components such as surfactants, and thus exhibit no toxicity in vivo, demonstrating excellent safety.

[0057] Figure 1 is a schematic diagram of cholesterol metabolism in normal brain cells, cholesterol metabolism in GBM cells, and the mechanism of GBM death by 24HC-containing rHDL nanoparticles.

[0058] Figure 2 is a graph comparing CYP46A1 RNA levels in normal and GBM brain samples based on TCGA (The Cancer Genome Atlas) and GTEx (Genotype-tissue expression).

[0059] Figure 3 is a graph comparing LDLR RNA levels in normal and GBM brain samples based on TCGA (The Cancer Genome Atlas) and GTEx (Genotype-tissue expression).

[0060] Figure 4 is a graph comparing the amount of 24HC in astrocytes and GBM.

[0061] Figure 5 is a graph comparing the amount of cholesterol in astrocytes and GBM.

[0062] Figure 6 is a schematic diagram of a microfluidic device for manufacturing rHDL nanoparticles and a schematic diagram of a particle manufacturing method.

[0063] Figure 7 is a graph showing the DLS measurement results showing the size distribution of rHDL nanoparticles according to volume.

[0064] Figure 8 is a graph showing the size distribution of nanoparticles by volume according to the molar ratio of apolipoprotein E3:24HC synthesis when producing rHDL nanoparticles containing 24HC.

[0065] Figure 9 is a graph showing the size distribution of nanoparticles according to the intensity according to the molar ratio of apolipoprotein E3:24HC synthesis when producing rHDL nanoparticles containing 24HC.

[0066] Figure 10 is a graph showing the size distribution of nanoparticles according to the number of apolipoprotein E3:24HC synthetic molar ratios when producing rHDL nanoparticles containing 24HC.

[0067] Figure 11 is a graph showing the loading amount of 24HC in rHDL nanoparticles containing 24HC according to the molar ratio of apolipoprotein E3:24HC synthesis.

[0068] Figure 12 is a graph showing the size distribution of 24HC-containing rHDL nanoparticles produced with a synthetic molar ratio of apolipoprotein E3:24HC of 1:3, according to volume, as measured by DLS.

[0069] Figure 13 is a graph showing the composition ratio of apolipoprotein E3 and phospholipids in rHDL nanoparticles.

[0070] Figure 14 is a graph showing the composition ratio of apolipoprotein E3, phospholipid, and 24HC in rHDL nanoparticles containing 24HC.

[0071] Figure 15 is a graph showing changes in particle size for up to 24 hours to measure the stability of rHDL nanoparticles and 24HC-containing rHDL nanoparticles under serum conditions.

[0072] Figure 16 is a graph showing changes in particle size for up to 24 hours to measure the stability of rHDL nanoparticles and 24HC-containing rHDL nanoparticles under GBM tissue pH conditions.

[0073] Figure 17 is a graph showing changes in particle size for up to 24 hours to measure the stability of rHDL nanoparticles and 24HC-containing rHDL nanoparticles under body fluid pH conditions.

[0074] Figure 18 is a graph showing particle size change for stability measurement of rHDL nanoparticles and 24HC-containing rHDL nanoparticles for 60 days under 4 conditions.

[0075] Figure 19 is a graph showing the PDI stability of rHDL nanoparticles and 24HC-containing rHDL nanoparticles for 60 days under 4°C conditions.

[0076] Figure 20 is a photograph showing the results of confirming the cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles into hBMEC cells using CLSM.

[0077] Figure 21 is a graph showing the CLSM data of cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles in hBMEC cells, quantified using Image J.

[0078] Figure 22 is a photograph showing the results of confirming the cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles into iBMEC cells using CLSM.

[0079] Figure 23 is a graph showing the CLSM data of cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles in iBMEC cells, quantified using Image J.

[0080] Figure 24 is a graph showing the results of evaluating cell permeability when rHDL nanoparticles and 24HC-containing rHDL nanoparticles are treated in hBMEC cells.

[0081] Figure 25 is a graph showing the results of evaluating hBMEC cytotoxicity when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0082] Figure 26 is a graph showing the results of evaluating iBMEC cytotoxicity when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0083] Figure 27 is a graph showing the results of evaluating pericyte cell toxicity when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0084] Figure 28 is a graph showing the results of evaluating astrocyte cytotoxicity when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0085] Figure 29 is a photograph showing the results of confirming the cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles through LDLR in U87MG cells using CLSM.

[0086] Figure 30 is a graph showing the CLSM results of cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles through LDLR in U87MG cells, quantified using Image J.

[0087] Figure 31 is a photograph showing the results of confirming the cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles through LDLR in LN229 cells using CLSM.

[0088] Figure 32 is a graph showing the CLSM results of cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles through LDLR in LN229 cells, quantified using Image J.

[0089] Figure 33 is a graph comparing the changes in 24HC in U87MG and LN229 cells upon treatment with 24HC and 24HC-containing rHDL nanoparticles with respect to 24HC.

[0090] Figure 34 is a graph showing the change in LDLR mRNA expression in U87MG and LN229 cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0091] Figure 35 is a graph showing the change in ABCA1 mRNA expression in U87MG and LN229 cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0092] Figure 36 is a graph showing changes in cholesterol efflux in U87MG and LN229 cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0093] Figure 37 is a graph showing the change in cholesterol efflux in U87MG and LN229 cells when treated with rHDL nanoparticles and 24HC-containing rHDL nanoparticles with or without an ABCA1 inhibitor.

[0094] Figure 38 is a graph showing the results of evaluating the apoptotic efficacy of U87MG cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0095] Figure 39 is a graph showing the results of evaluating the LN229 cell killing efficacy when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0096] Figure 40 is a photograph showing the results of confirming the cell influx of rHDL nanoparticles and 24HC-containing rHDL nanoparticles into GBM#P1 and GBM#P2 ​​cells using CLSM.

[0097] Figure 41 is a graph showing the CLSM results of cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles in GBM#P1 cells, quantified using Image J.

[0098] Figure 42 is a graph showing the CLSM results of cell uptake of rHDL nanoparticles and 24HC-containing rHDL nanoparticles in GBM#P2 ​​cells, quantified using Image J.

[0099] Figure 43 is a graph showing the change in LDLR mRNA expression in GBM#P1 and GBM#P2 ​​cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0100] Figure 44 is a graph showing changes in ABCA1 mRNA expression in GBM#P1 and GBM#P2 ​​cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0101] Figure 45 is a graph showing the change in cholesterol efflux within GBM#P1 and GBM#P2 ​​cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0102] Figure 46 is a graph showing the change in cholesterol efflux in GBM#P1 and GBM#P2 ​​cells when treated with rHDL nanoparticles and 24HC-containing rHDL nanoparticles with or without an ABCA1 inhibitor.

[0103] Figure 47 is a graph showing the results of evaluating the apoptotic efficacy of GBM#P1 cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0104] Figure 48 is a graph showing the results of evaluating the apoptotic efficacy of GBM#P2 ​​cells when treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles.

[0105] The term "reconstituted high-density lipoprotein (rHDL)" as used herein refers to artificially manufactured HDL-mimetic particles intended to mimic the biological effects of naturally occurring high-density lipoprotein (HDL).

[0106] The term "24-hydroxycholesterol" as used herein refers to a type of oxysterol, an oxidized derivative of cholesterol that is produced through endogenous cholesterol metabolism in tissues and participates in the regulation of cholesterol metabolism, and is also referred to as "24HC".

[0107] The term "phospholipid" as used herein specifically refers to 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), 1,2-Diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1,2-Diicosanoyl-sn-glycero-3-phosphocholine (DEPC), Palmitoyloleoylphosphatidylcholine (POPC), Lysophosphatidylcholine, Dilinoleoylphosphatidylcholine, Distearoylphosphatidylethanolamine (DSPE), Dimyristoylphosphatidylethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), Palmitoyloleoylphosphatidylethanolamine (POPE), Lysophosphatidylethanolamine, N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide)(VL-5), Dioctadecylamidoglyclespermine 4-trifluoroacetic acid (DOGS), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), (1,2-dioleyloxypropyl)-3-dimethylhydroxyethyl ammonium bromide (DORIE), 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanammonium bromide (GAP-DLRIE), Nt-butyl-N'-tetradecyl-3-tetradecylaminopropionamidine (diC14-amidine), ethylphosphocholine (Ethyl PC), dimethyldioctadecylammonium bromide (DDAB), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), or one or more selected from the group consisting of D-Lin-MC3-DMA (MC3, DLin-MC3-DMA), DLin-KC2-DMA, DLin-DMA, but is not limited thereto.

[0108] The term "cholesterol" used herein refers to a type of sterol, a steroid alcohol, and a lipid component that constitutes a cell membrane, and preferably cholesterol, 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 4β-hydroxycholesterol, α-5,6-epoxycholesterol, β-5,6-epoxycholesterol, 24S, 25-epoxycholesterol, 25-epoxycholesterol, 7-hydroxycholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(R)-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 5β-epoxycholesterol, 6β-epoxycholesterol, 7-dehydrocholesterol, (25R)26-hydroxycholesterol, 7α,(25R)26-dihydroxycholesterol, 5β-cholestane-3α,7α,12α,(25R)26-tetrol(25R)26-tetrol), 7α,25-dihydroxycholesterol, 7α,24S-dihydroxycholesterol, 3β,5α,6β-cholestane-3,5,6,26-tetrol, Lanosterol, Desmosterol, 7α-hydroxydesmosterol, (24Z),26S-hydroxydesmosterol, (24E),26S-hydroxydesmosterol, 24S,25-epoxylanosterol, 26(Z)-hydroxydesmosterol, 25-hydroxy-8-dehydrocholesterol, 24-hydroxy-8-dehydrocholesterol, 7-dehydrocholesterol, 8-dehydrocholesterol, (25R)26-hydroxy-8-dehydrocholesterol, 25-hydroxy-7-dehydrocholesterol, 4α-hydroxy-7-dehydrocholesterol, 4β-hydroxy-7-dehydrocholesterol, 7,8-epoxycholesterol, 3α,5β,6α-cholestane-3,6-diol, cholestan-3β, 5α, 6β-triolIt may be at least one selected from the group consisting of, but is not limited to, 6β-triol), Oxy34, Oxy49, and Oxy133.

[0109] The term "LXR promoter" as used herein refers to a substance that promotes transcription of liver X receptor (LXR), and the LXR promoter can activate cholesterol efflux genes (ABCA1, ABCG1) by promoting transcription of LXR to increase expression, thereby causing excessive cholesterol efflux and downregulating cholesterol absorption. The LXR promoter may preferably be at least one selected from the group consisting of T0901317, GW3965, GW6340, DMHCA, LXR-623, WYE-672, AZ876, but is not limited thereto.

[0110] The above T0901317 is an LXR promoter and has the chemical formula 1 below.

[0111] [Chemical Formula 1]

[0112] C 17 H 12 NSO3F9(T0901317)

[0113]

[0114] The above GW3965 is an LXR promoter and has the chemical formula 2 below.

[0115]

[0116] [Chemical Formula 2]

[0117] C 33 H 31 F3ClNO3(GW3965)

[0118]

[0119]

[0120] The above GW6340 is an LXR promoter and has the chemical formula 3 below.

[0121]

[0122] [Chemical Formula 3]

[0123] C 33 H 32 ClF3N2O (GW6340)

[0124]

[0125] The above DMHCA is an LXR promoter and has the chemical formula 4 below.

[0126]

[0127] [Chemical Formula 4]

[0128] C 26 H 43 NO2(DMHCA)

[0129]

[0130]

[0131] The above LXR-623 is an LXR promoter and has the chemical formula 5 below.

[0132]

[0133] [Chemical Formula 5]

[0134] C 21 H 12 ClF5N2(LXR-623)

[0135]

[0136]

[0137] The above WYE-672 is an LXR promoter and has the chemical formula 6 below.

[0138]

[0139] [Chemical Formula 6]

[0140] C 23 H 17 F3N2O2S (WYE-672)

[0141]

[0142]

[0143] The above AZ876 is an LXR promoter and has the chemical formula 7 below.

[0144]

[0145] [Chemical Formula 7]

[0146] C 24 H 29 N3O3S (AZ876)

[0147]

[0148]

[0149] The term "ShK" as used herein refers to Stichodactyla toxin or a derivative thereof, including Stichodactyla toxin in which the terminal end is substituted with an NHS functional group or the like. ShK refers to a peptide or a derivative thereof that has the function of inhibiting intracellular potassium channels and restoring nerve cells. The ShK has the amino acid sequence of the following chemical formula 8.

[0150]

[0151] [Chemical Formula 8]

[0152]

[0153]

[0154] As used herein, the term "apolipoprotein E" refers to a mammalian protein encoded by the APOE gene or a functional variant thereof. In a preferred embodiment, apolipoprotein E is a human protein encoded by the human APOE gene on chromosome 19. Apolipoprotein E can be any of the isoforms of the APOE gene product, such as apolipoprotein E2 ("APOE2"), apolipoprotein E3 ("APOE3"), and apolipoprotein E4 (APOE4). APOE is a polymorphism with three major alleles (epsilon 2, epsilon 3, and epsilon 4). Any of the alleles can be used in various embodiments of the present invention. A "functional variant" thereof refers to a variant of the mammalian protein encoded by the APOE gene that retains the same or similar biological function as the APOE gene product. In some cases, functional variants comprise amino acid insertions, deletions, and / or substitutions compared to a protein encoded by the human APOE gene. In some cases, functional variants are fragments of a protein encoded by the human APOE gene.

[0155] In some embodiments, the apolipoprotein E2 is a protein disclosed in GenBank under Accession No. ARQ79459 or is at least 95% sequence identical thereto, preferably at least 98% or 99% sequence identical thereto. In some embodiments, the apolipoprotein E3 is a protein disclosed in GenBank under Accession No. ARQ79461.1 or is at least 95% sequence identical thereto, preferably at least 98% or 99% sequence identical thereto.

[0156] In some embodiments, the apolipoprotein E in the reconstituted high-density lipoprotein (rHDL) is a recombinant protein produced by genetic engineering or a synthetic protein produced by chemical synthesis.

[0157] The term "apolipoprotein A1" refers to a mammalian protein encoded by the APOA1 gene or a functional variant thereof. In a preferred embodiment, apolipoprotein A1 is a human protein encoded by the human APOA1 gene located on chromosome 11. A "functional variant" thereof refers to a variant of the mammalian protein encoded by the APOA1 gene that retains the same or similar biological function as the APOA1 gene product. In some cases, the functional variant comprises amino acid insertions, deletions, and / or substitutions compared to the protein encoded by the human APOA1 gene. In some cases, the functional variant is a fragment of a protein encoded by the human APOA1 gene.

[0158] In some embodiments, the apolipoprotein A1 is a protein disclosed in GenBank under accession number AAS68227.1 or a protein having at least 95% sequence identity thereto, preferably at least 98% or 99% sequence identity thereto.

[0159] The term “apolipoprotein E” as used herein is meant to include fragments and functional variants thereof.

[0160] The term "microfluidic device" as used herein means a device that includes microchannels, etc., that allow fluid to flow on a substrate made of various materials including plastic, glass, metal, or silicon containing organic polymer materials.

[0161] The term "microcolumn" or "microcolumn structure" as used herein refers to a column-shaped structure for forming a vortex within a microfluidic device to efficiently mix different types of fluids injected into the microfluidic device.

[0162] The term "prevention" as used herein means any action that inhibits or delays the onset of a disease by administering a composition, and "treatment" means any action that improves or beneficially changes the symptoms of a subject suspected of or suffering from a disease by administering a composition.

[0163] The term "cancer" as used herein may be one or more selected from the group consisting of carcinoma, sarcoma, lymphoma, leukemia, germ cell tumor, brain tumor corresponding to blastoma, cervical cancer, ovarian cancer, prostate cancer, lung cancer, bile duct cancer, kidney cancer, stomach cancer, liver cancer, retinoblastoma, choriocarcinoma, small intestine cancer, colon cancer and rectal cancer, non-small cell lung cancer, gastric adenocarcinoma, acute lymphoblastic leukemia, acute myeloid leukemia, breast cancer, bone sarcoma, bladder cancer, anaplastic astrocytoma, head and neck cancer, pancreatic cancer and esophageal cancer, but is not limited thereto.

[0164] The present invention will be described in more detail through the following examples, but the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[0165]

[0166] [Example 1]

[0167] Comparison of cholesterol metabolic factors and intracellular cholesterol in normal brain astrocytes and GBM cells.

[0168] Cholesterol is a vital nutrient for normal cellular function and survival. It plays a crucial role in the plasma membrane and lipid rafts, and is a precursor of steroid hormones, bile acids, and vitamin D. Because too much or too little intracellular cholesterol can be toxic, cells regulate intracellular cholesterol homeostasis through cholesterol uptake, efflux, and endogenous synthesis. The sterol-responsive nuclear liver X receptor (LXR) regulates cholesterol homeostasis by activating cholesterol efflux genes (ABCA1, ABCG1) as well as inducing low-density lipoprotein receptor (LDLR) degradation.

[0169] Cholesterol homeostasis is a hallmark of cancer. Abnormally high cholesterol levels in many cancers, including liver, stomach, colon, pancreatic, and prostate cancers, affect cancer progression, including proliferation, metastasis, and invasion. Excessive cholesterol levels in cancer cells arise from increased LDLR-mediated exogenous cholesterol uptake, inhibition of ABCA1-mediated cholesterol efflux, or increased cholesterol synthesis.

[0170] Figure 1 is a schematic diagram comparing cholesterol metabolism in normal brain astrocytes and GBM cells and a schematic diagram illustrating the GBM death mechanism by 24HC-containing rHDL nanoparticles. Normal human astrocytes maintain intracellular cholesterol homeostasis by converting excess intracellular cholesterol into 24HC by the cytochrome P450 enzyme cholesterol 24-hydroxylase (CYP46A1) (Cytochrome P450 Family 46 Subfamily A Member 1). 24HC is an LXR agonist that activates LXR, thereby reducing intracellular cholesterol by suppressing LDLR expression involved in cholesterol uptake and increasing ABCA1 and ABCG1 involved in cholesterol efflux. GBM cells are known to have relatively low CYP46A1 compared to normal cells, resulting in low levels of intracellular 24HC. Therefore, in the present invention, 24HC-containing rHDL nanoparticles are delivered into GBM cells to increase 24HC, an LXR agonist, and consequently cause cell death due to depletion of intracellular cholesterol.

[0171] Interestingly, GBM cells cannot synthesize new cholesterol through the mevalonate pathway and rely on cholesterol uptake via the LDLR. We investigated RNA gene expression in GBM and normal brain samples using data from The Cancer Genome Atlas (TCGA) and Genotype-tissue expression (GTEx).

[0172] As shown in Figure 2, analysis of RNA genes related to cholesterol metabolism enzymes in TCGA revealed that the expression of CYP46A1, which converts cholesterol to 24HC, was lower in GBM compared to normal brain tissue. This suggests that GBM cells have a reduced ability to convert cholesterol to 24HC compared to normal cells.

[0173] As shown in Figure 3, analysis of the LDLR RNA gene in TCGA revealed that LDLR RNA expression was higher in GBM compared to normal brain tissue. Because GBM lacks intracellular cholesterol synthesis and relies on exogenous cholesterol via LDLR, LDLR is overexpressed compared to normal brain tissue.

[0174] We compared the levels of 24HC and cholesterol in astrocytes, which can replace normal brain cells, and in representative GBM cell lines, U87MG and LN229. Astrocytes were cultured in poly-L-lysine-coated flasks using AM medium. U87MG cells were cultured in MEM medium, and LN229 cells in DMEM medium, each supplemented with 10% FBS and 1% P / S (penicillin-streptomycin). Each cell was cultured at 37°C in a 5% CO2 atmosphere and 95% relative humidity. Indeed, we found that the levels of 24HC in U87MG and LN229 cells were significantly lower than those in astrocytes (Fig. 4), suggesting that this substantially induces excessive cholesterol accumulation in GBM cells (Fig. 5).

[0175]

[0176] [Example 2]

[0177] Method for manufacturing rHDL nanoparticles containing 24HC

[0178] A microfluidic device was designed to produce rHDL nanoparticles by mixing phospholipids and apolipoproteins (Fig. 6). The microfluidic device included three inlets and one outlet. Hydrophobic phospholipids were introduced through the central inlet of the three inlets, and hydrophilic apolipoproteins were introduced through the two inlets on either side. In addition, a micropillar structure was introduced into the microfluidic device to effectively mix lipids and apolipoproteins.

[0179] Using the above microfluidic device, nanoparticles containing phospholipids and apolipoproteins were manufactured as follows. A DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) solution in absolute ethanol and an apolipoprotein E3 solution in phosphate-buffered saline (PBS) were prepared. Then, about 0.8 mL of the DMPC solution in absolute ethanol at a concentration of 0.83 mg / mL was filled into one syringe, and about 1.25 mL each (about 2.5 mL in total) of the same amount of the apolipoprotein solution in PBS at a concentration of 0.2 mg / mL was filled into the other two syringes, and then bubbles in all syringes were removed.

[0180] Each syringe needle was connected to the inlet of the microfluidic device using a tube, and PBS was flowed at an outlet speed of 1 mL / min to wash the microfluidic device. Thereafter, the injection flow rate of the DMPC solution was set to 0.8 mL / min and the injection flow rate of the apolipoprotein E3 solution was set to 4.4 mL / min using a syringe pump.

[0181] The rHDL nanoparticles manufactured through the outlet of the microfluidic device were obtained, and the obtained rHDL nanoparticles were mixed with PBS, and then purified three times using a 10K filter at the maximum speed of a centrifuge at 4°C for 20 minutes.

[0182] 24HC (molecular weight 402.7 g / mol) in DMSO was prepared at a concentration of 1 mg / mL. The apolipoprotein E3 concentration of the obtained rHDL nanoparticles was measured, and 24HC was added dropwise to each nanoparticle so that the molar ratio of apolipoprotein E3:24HC was 1:2, 1:3, and 1:4. At this time, the amount of DMSO was not more than 10% of the total amount of 24HC-containing rHDL nanoparticles to be finally manufactured. After storing at room temperature for 12-16 hours, the nanoparticles were mixed with PBS, and then purified using a 10K filter at the maximum centrifuge speed at 4°C for 20 minutes.

[0183]

[0184] [Example 3]

[0185] Method for preparing rHDL nanoparticles containing ShK

[0186] rHDL nanoparticles manufactured in the same manner as in Example 2 were obtained, and the obtained rHDL nanoparticles were mixed with PBS, and purified three times using a 10K filter at 4°C for 20 minutes at the maximum speed of a centrifuge.

[0187] Hydroxysuccinimide cholesterol solution in anhydrous acetonitrile and ShK (6-FAM-AEEAc-Stichodactyla helianthus neurotoxin (ShK) trifluoroacetate salt) solution in PBS were prepared. The cholesterol solution and ShK solution were mixed in a 1:2 molar ratio and reacted at room temperature for 4 hours. Then, the mixture was purified three times using a 3K filter at maximum centrifugal speed for 20 minutes at 4°C to prepare a ShK-cholesterol solution.

[0188] The prepared rHDL nanoparticle solution and ShK-cholesterol solution were mixed in a 1:2 molar ratio using a vortex mixer and reacted at room temperature for 4 hours. Thereafter, the solution was purified once using a 10k filter at maximum centrifugal speed at 4°C for 20 minutes to prepare rHDL nanoparticles containing ShK-cholesterol.

[0189]

[0190] [Example 4]

[0191] Optimization of the blending ratio of apolipoprotein E3 and 24HC for the synthesis of 24HC-containing rHDL nanoparticles.

[0192] To synthesize 24HC-containing rHDL nanoparticles, the following experiments were conducted to find the optimal molar ratio of apolipoprotein and cholesterol containing 24HC. Apolipoprotein E3:24HC was synthesized at molar ratios of 1:2, 1:3, and 1:4, respectively, and the average size and size distribution of 24HC-containing rHDL nanoparticles according to the mixing ratio were compared.

[0193] After dissolving 24HC-containing rHDL nanoparticles prepared by varying the molar ratio of apolipoprotein E3:24HC in the same manner as in Example 2 above in PBS, the change in particle size distribution due to nanoparticle aggregation was measured using dynamic light scattering (DLS) using Zetasizer Nano ZS.

[0194] By volume (n=3) ApoE3:24HC (molar ratio) Size (nm) Volume (%) 1:218.2 ± 5.4 16.9 ± 1.1 1:319.7 ± 7.3 18.6 ± 3.4 1:421.7 ± 1.9 19.2 ± 1.8

[0195] As shown in Table 1 and FIGS. 8 to 10, it can be seen that the 24HC-containing rHDL nanoparticles synthesized according to each molar ratio of the present invention have a size of 25 nm or less.

[0196] To determine the amount of 24HC encapsulated in 24HC-containing rHDL nanoparticles, 24HC was quantified using a cholesterol quantification kit. The results are shown in Table 2 below.

[0197]

[0198] No. ApoE3:24HC (molar ratio) ApoE3 input (mg) 24HC input (μg) Final encapsulated 24HC (μg) 24HC encapsulation rate (%) 11:20.7 14.4 9.6 6.7 2 1:30.7 2 4 19.9 8 3.0 3 1:40.7 3 2 19.5 6 1.0

[0199]

[0200] As shown in Table 2 above, when the synthetic molar ratio of 24HC to apolipoprotein E3 of rHDL nanoparticles was 1:2 and 1:4, the encapsulation rate of 24HC was 61-67%, while the encapsulation rate was the highest at 83% when the synthetic molar ratio was 1:3 (Fig. 11). It can be seen that there is a limit to the encapsulation of 24HC even when the synthetic molar ratio of 24HC to apolipoprotein E3 of rHDL nanoparticles is 1:3 or higher. Therefore, the 24HC-containing rHDL nanoparticles with the highest 24HC encapsulation rate, which are the synthetic molar ratios of 24HC to apolipoprotein E3 of rHDL nanoparticles of 1:3, were selected as the final particles.

[0201] In the case of rHDL nanoparticles, the particle size was 16.8 nm (Fig. 7), whereas when the synthetic molar ratio of 24HC to apolipoprotein E3 of rHDL nanoparticles was 1:3 or higher, the size was 18.6 nm (Fig. 12), confirming that the size increased as 24HC was encapsulated.

[0202] In order to confirm the final composition ratio of apolipoprotein E3, phospholipid, and 24HC of 24HC-containing rHDL nanoparticles having a molar ratio of 24HC to apolipoprotein E3 of 1:3 according to the manufacturing method of Example 2, BCA assay, lipid quantification kit, and cholesterol quantification kit were used to quantify them. The results are shown in Table 3 and Figures 13 and 14.

[0203]

[0204] ApoE3 (%) DMPC (%) 24HC (%) rHDL nanoparticles 67.033.0-24HC containing rHDL nanoparticles 64.833.12.2

[0205] As shown in Table 3 above, both rHDL nanoparticles and 24HC-containing rHDL nanoparticles had similar compositions with a lipid content of 33%, but it was confirmed that the 24HC-containing rHDL nanoparticles had a lower protein composition than rHDL nanoparticles due to the 24HC component.

[0206] [Example 5]

[0207] Stability verification of rHDL nanoparticles and 24HC-containing rHDL nanoparticles

[0208] Stability tests were performed on rHDL nanoparticles and 24HC-containing rHDL nanoparticles, respectively, under serum and high ionic strength conditions. Both nanoparticles were diluted in serum (FBS, fatal bovine serum) (Figure 15), phosphate-buffered saline (pH 6.8; GBM pH) (Figure 16), and saline (pH 7.0; body fluid pH) (Figure 17) and incubated at 37°C. After dissolving a fixed amount of nanoparticles in PBS at designated times (0, 2, 4, 8, and 24 h), the particle sizes were measured. It was confirmed that both nanoparticles maintained their initial particle sizes for up to 24 h under the three conditions described above. Furthermore, both nanoparticles maintained their initial particle sizes (Figure 18) and particle dispersity indices (Figure 19) stably for 60 days at 4°C. These results demonstrate that both nanoparticles are stable in vivo and have excellent storage stability.

[0209]

[0210] [Example 6]

[0211] Evaluation and comparison of blood-brain barrier cell influx and permeability of rHDL nanoparticles and 24HC-containing rHDL nanoparticles.

[0212] It was confirmed whether the rHDL nanoparticles and 24HC-containing rHDL nanoparticles manufactured according to the manufacturing method of Example 2 could penetrate the blood-brain barrier (BBB) ​​and be delivered to the brain. Cell uptake experiments were performed using human brain microvascular endothelial cells (hBMEC) and human iPSC-derived brain microvascular endothelial cells (iBMEC) using the following method. hBMEC and iBMEC cells were cultured in flasks coated with collagen IV / fibronectin, and ECM medium was used for hBMEC cells, and hESFM+B27+bFGF+RA medium was used for iBMEC cells. After 24 hours of culture, the iBMEC cells were replaced with hESFM+B27 medium. Each cell was cultured at 37°C in an atmosphere of 5% CO2 and 95% relative humidity. hBMEC and iBMEC cells were seeded in confocal dishes at 2X10 5 , 1.2Х10 5After seeding into cells / confocal dish and culturing for 24 h, each cell was treated with DiD-labeled rHDL nanoparticles and DiD-labeled 24HC-containing rHDL nanoparticles for 4 h using FBS- and P / S-free medium. After 4 h, the supernatant was completely removed, washed with PBS, and the cells were fixed with 4% paraformaldehyde (PFA) solution for 10 min. After removing the 4% PFA solution, mounting medium with DAPI and Microtubule Stain reagent were added, and coverslips were covered. The cells were observed using a confocal microscope (CLSM, Confocal Laser Scanning Microscopy). It was confirmed that both DiD-rHDL nanoparticles and DiD-24HC-containing rHDL nanoparticles were incorporated into hBMEC (Fig. 20) and iBMEC (Fig. 22) (scale bar: 50 μm). Quantification of intracellularly delivered rHDL nanoparticles (Fig. 21) and 24HC-containing rHDL nanoparticles (Fig. 23) using Image J revealed no difference in the intracellular delivery amounts of the two nanoparticles. This indicates that even if 24HC is included in rHDL nanoparticles, there is no change in the BBB delivery of rHDL.

[0213] To confirm the BBB penetration efficiency of rHDL nanoparticles and 24HC-containing rHDL nanoparticles, a BBB penetration experiment was performed using hBMEC using the following method. hBMEC were placed in the inset well of a collagen IV / fibronectin-coated transwell at a density of 3.3X10 5Cells / well dish were cultured for 48 hours. After treating the cells with DiD-labeled rHDL nanoparticles and DiD-labeled 24HC-containing rHDL nanoparticles for 24 hours, quantitative analysis of nanoparticles permeated from the bottom well was performed. As shown in Fig. 24, there was no difference in hBMEC permeability between rHDL nanoparticles and 24HC-containing rHDL nanoparticles, confirming that permeation was high. This confirms that in the case of 24HC-containing rHDL nanoparticles, even when 24HC is contained in the rHDL nanoparticles, the BBB permeability of rHDL is the same as that of rHDL without losing its ability to permeate the BBB. In conclusion, it was confirmed that rHDL nanoparticles and 24HC-containing rHDL nanoparticles permeate the BBB and are delivered to the brain.

[0214]

[0215] [Example 7]

[0216] Safety evaluation of 24HC-containing rHDL nanoparticles in blood-brain barrier cells (hBMEC, iBMEC, pericyte) and brain astrocytes

[0217] The toxicity of 24HC-containing rHDL nanoparticles to hBMEC, iBMEC, pericytes, and astrocytes, which constitute the BBB, before they penetrate the BBB and reach the GBM was evaluated. hBMEC, iBMEC, pericytes, and astrocytes were seeded in 96-well cell culture plates. Pericyte cells were cultured in PM medium, astrocyte cells were cultured in the same culture medium as described in Example 1, and hBMEC and iBMEC cells were cultured in the same culture medium as described in Example 6. After 24 hours of incubation, the cells were treated with the nanoparticles of the present invention at 0-5 μg / mL, respectively, and the cell viability (%) was evaluated after 8 hours of incubation. As shown in Figures 25 to 28, none of the rHDL nanoparticles, 24HC, or 24HC-containing rHDL nanoparticles showed toxicity to hBMEC, iBMEC, pericytes, and astrocytes. These results demonstrate that the nanoparticles of the present invention can be delivered to the brain without toxicity when crossing the BBB. Furthermore, they demonstrate no toxicity to normal brain cells other than GBM.

[0218]

[0219] [Example 8]

[0220] Confirmation of intracellular uptake of 24HC-containing rHDL nanoparticles through LDLR in GBM

[0221] ApoE consists of two independently folded structural domains: a high-lipid binding domain (C-terminal domain) and an LDLR-binding domain (N-terminal domain). Interestingly, the ApoE3-lipid complex, i.e., rHDL, has a stronger binding capacity to the LDLR-binding domain (residues 140–150) than ApoE. Therefore, based on the finding that lipid binding induces a conformational change and confers LDLR recognition properties, we hypothesized that rHDL would be a suitable nanoparticle for delivering 24HC to GBM overexpressing LDLR.

[0222] The cellular uptake mechanism of 24HC-containing rHDL nanoparticles was evaluated in U87MG and LN229 cells, which are GBM cells with overexpression of LDLR. To determine whether the rHDL nanoparticles of the present invention and 24HC-containing rHDL nanoparticles are taken up into cells through LDLR of GBM, LDL (low density lipoprotein, human) was used as a competitive inhibitor. U87MG and LN228 were cultured in the same culture medium and conditions as described in Example 1. After 24 hours of culture, each cell was pretreated with 50 μg / mL LDL in a medium without FBS and P / S for 2 hours. Each cell was treated with Cy5.5-labeled rHDL nanoparticles (Cy5.5-rHDL nanoparticles) and Cy5.5-labeled 24HC-containing rHDL nanoparticles (Cy5.5-24HC-containing rHDL nanoparticles) for 4 hours, respectively. After 4 hours, the supernatant was completely removed, washed with PBS, and the cells were fixed with 4% paraformaldehyde (PFA) solution for 10 minutes. The 4% PFA solution was then removed, mounting medium with DAPI reagent was added, and a cover glass was placed over the cells and observed using a confocal microscope (CLSM, Confocal Laser Scanning Microscopy).

[0223] The cellular uptake efficiency of rHDL nanoparticles and 24HC-containing rHDL nanoparticles was quantitatively analyzed using Image J software. To determine the cellular fluorescence level in fluorescence microscopy images, corrected total cell fluorescence (CTCF) was performed for each cell. Individual cells were selected using the freehand drawing tool to create a region of interest (ROI). The average background level was obtained by measuring the intensity in three different regions outside the cells and averaging the values ​​obtained. The CTCF for each cell was calculated using the following formula:

[0224] CTCF = Integrated density of cell ROI - (mean fluorescence of ROI area Х background)

[0225] As shown in Figs. 29 and 31, the results of comparison of the intracellular uptake of Cy5.5-rHDL nanoparticles and Cy5.5-24HC-containing rHDL nanoparticles are shown (scale bar is 50 μm). Both Cy5.5-rHDL nanoparticles and Cy5.5-24HC-containing rHDL nanoparticles were taken up into the cytoplasm, and interestingly, the intracellular uptake of Cy5.5-rHDL nanoparticles and Cy5.5-24HC-containing rHDL nanoparticles was inhibited by pretreatment with LDL, a competitive inhibitor of LDLR. As shown in Figs. 30 and 32, the results of quantifying the nanoparticles delivered into the cells confirmed that the intracellular uptake of nanoparticles was inhibited in the group pretreated with LDLR. These results confirmed that the nanoparticles of the present invention were taken up into the cells through LDLR, and that the intracellular uptake was also through LDLR even when they contained 24HC.

[0226] To confirm that treating GBM with 24HC-containing rHDL nanoparticles delivers 24HC into cells more efficiently through LDLR of GBM than treating GBM with 24HC solution alone, cells were treated with 24HC solution and 24HC-containing rHDL nanoparticles, and the amount of 24HC within the cells was quantified using a 24(S)-hydroxycholesterol ELISA kit. It was confirmed that the amount of 24HC within the cells was higher in the group treated with 24HC-containing rHDL nanoparticles compared to the 24HC solution (Fig. 33). The amount of 24HC within the cells increased by 40% and 20% after treatment with 24HC-containing rHDL nanoparticles compared to the 24HC treatment alone in U87MG and LN229, respectively. While 24HC is transported vertically from the outer to the inner layer of the cell membrane via local diffusion, 24HC-containing rHDL nanoparticles rapidly deliver 24HC into cells via the LDLR receptor. Consistent with our results, 24HC-containing rHDL nanoparticles targeted LDLR overexpression in GBM, increasing 24HC uptake and accumulation compared to 24HC solution. This confirms that the rHDL nanoparticles of the present invention serve as drug delivery vehicles for more effectively delivering 24HC into GBM cells than 24HC solution alone.

[0227]

[0228] [Example 9]

[0229] Changes in LDLR and ABCA1 mRNA expression in GBM treated with 24HC-containing rHDL nanoparticles

[0230] 24HC is an endogenous LXR agonist that induces the expression of genes such as ABCA1 and ABCG1, which are responsible for cholesterol efflux, thereby inducing intracellular cholesterol efflux, and is also known to inhibit exogenous cholesterol uptake by reducing LDLR. Therefore, we expected that the LDLR-reducing and ABCA1-increasing effects due to the action of 24HC would be greater when treating GBM with 24HC-containing rHDL nanoparticles than when treated with 24HC alone. Therefore, we treated U87MG and LN229 cells with 24HC, 24HC-containing rHDL nanoparticles, and rHDL nanoparticles, and confirmed the changes in LDLR and ABCA1 mRNA expression using qPCR (Real-Time polymerase chain reaction).

[0231] U87MG and LN229 cells were seeded in 6-well cell culture plates at a density of 0.5X10 5 cells / well and cultured for 24 hours under the conditions described in Example 1. In qPCR experiments, the nanoparticles mentioned above were treated with 24HC at a concentration of 1 μg / mL for U87MG cells and 5 μg / mL for LN229 cells for 24 hours to confirm changes in LDLR mRNA, and ABCA1 mRNA was confirmed after treatment for 4 hours. In the case of rHDL nanoparticles, the amount of apolipoprotein E3 in the 24HC-containing rHDL nanoparticles was quantified using a BCA assay, and then the same amount of apolipoprotein E3 corresponding to the 24HC treatment concentration was calculated before treating the rHDL nanoparticles.

[0232] Figures 34 and 35 show the results of changes in LDLR and ABCA1 mRNA expression in each cell in response to nanoparticle treatment of the present invention. When 24HC and 24HC-containing rHDL nanoparticles were treated to U87MG and LN229 cells, it was confirmed that LDLR mRNA expression decreased compared to the control group (Figure 34). The LDLR mRNA expression level in U87MG cells was 0.5 times lower in the 24HC-containing rHDL nanoparticle treatment group than in the control group and 0.8 times lower than in 24HC (Figure 34 ○). In the case of LN229 cells, the 24HC-containing rHDL nanoparticle treatment group was 0.2 times lower than in the control group and 0.3 times lower than in 24HC (Figure 34 △) (U87MG, LN229; ****p ≤ 0.0001).

[0233] Conversely, after treating U87MG and LN229 cells with 24HC and 24HC-containing rHDL nanoparticles, the ABCA1 mRNA expression level increased compared to the control group (Fig. 35). In U87MG cells, the ABCA1 mRNA expression level in the 24HC-containing rHDL nanoparticle-treated group was 2.7 times higher than that in the control group and 1.6 times higher than that in 24HC (Fig. 35 ○). In LN229 cells, the ABCA1 mRNA expression level in the 24HC-containing rHDL nanoparticle-treated group was 3.8 times higher than that in the control group and 1.1 times higher than that in 24HC (Fig. 35 △) (U87MG, LN229; ****p ≤ 0.0001).

[0234] As a result of comprehensive verification, it was confirmed that rHDL nanoparticles containing 24HC more significantly reduced the expression level of LDLR mRNA in cells and more significantly increased the expression level of ABCA1 mRNA than 24HC alone. This is thought to be because rHDL nanoparticles containing 24HC, as confirmed in Example 8, had a higher influx into GBM cells through LDLR compared to 24HC, and thus, 24HC was able to exhibit a higher LXR agonist effect when treated with rHDL containing 24HC.

[0235]

[0236] [Example 10]

[0237] Increased cholesterol efflux into GBM by 24HC-containing rHDL nanoparticles confirmed

[0238] We confirmed whether the increase in ABCA1 expression by 24HC-containing rHDL nanoparticles induced substantial intracellular cholesterol efflux. U87MG and LN229 cells were treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles, and the degree of intracellular cholesterol efflux was quantified using a cholesterol efflux kit. U87MG and LN229 cells were seeded at 1.2 x 105 cells / well in a 96-well cell culture plate, and the experimental method of the cholesterol efflux kit was followed. Each cell was treated with 24HC or 24HC-containing rHDL nanoparticles at a concentration of 1 μg / mL for U87MG cells and 5 μg / mL for LN229 cells for 24 hours. For rHDL nanoparticles, the amount of apolipoprotein E3 in 24HC-containing rHDL nanoparticles was quantified using a BCA assay, and then the rHDL nanoparticles were treated with the same amount of apolipoprotein E3 corresponding to the 24HC treatment concentration. After 24 hours, the fluorescence values ​​of cholesterol released into the extracellular and intracellular cholesterol were measured, respectively, and the cholesterol release rate (%) was calculated by calculating the value of released extracellular cholesterol in each treatment group compared to the intracellular cholesterol of the control group as a percentage (%).

[0239] Figure 36 shows the results of cholesterol efflux within each cell when treated with the nanoparticles of the present invention. In U87MG cells, cholesterol efflux (%) was 8.4 times higher in the 24HC-containing rHDL nanoparticle treatment group than in the control group, and 4.7 times higher than in 24HC (Figure 36 ○). In LN229 cells, cholesterol efflux (%) was 20.3 times higher in the 24HC-containing rHDL nanoparticle treatment group than in the control group, and 15.5 times higher than in 24HC (Figure 36 △) (U87MG, LN229; ***p ≤ 0.001, ****p ≤ 0.0001).

[0240] In conclusion, the greatest cholesterol efflux was observed in all cells when treated with 24HC-containing rHDL nanoparticles. The higher cholesterol efflux (%) observed in 24HC-containing rHDL nanoparticles compared to other treatment groups is thought to be due to the increased intracellular cholesterol efflux effect caused by the induction of increased ABCA1 mRNA expression, as shown in Example 9.

[0241] Using probucol, an ABCA1 inhibitor, we investigated whether 24HC-containing rHDL nanoparticles induce cholesterol efflux through increased ABCA1. U87MG and LN229 cells were pretreated with 40 μM Probucol for 4 h, and 24HC-containing rHDL nanoparticles and rHDL nanoparticles were treated with 5 μg / mL 24HC for 4 h, and the changes in cholesterol efflux were quantified using a cholesterol efflux kit. For rHDL nanoparticles, the amount of apolipoprotein E3 in 24HC-containing rHDL nanoparticles was quantified using a BCA assay, and then the same amount of apolipoprotein E3 corresponding to the 24HC treatment concentration was calculated before treating rHDL nanoparticles.

[0242] Figure 37 shows the results of confirming cholesterol efflux from each cell when treated with the nanoparticles of the present invention after treatment with an ABCA1 inhibitor. It was confirmed that cholesterol efflux was reduced in the nanoparticle-treated group after treatment with probucol, an ABCA1 inhibitor, compared to the group not treated with probucol. In U87MG cells, cholesterol efflux (%) in the 24HC-containing rHDL nanoparticle-treated group was reduced by 32.27% in the probucol-treated group (+) compared to the untreated group (-) (**p ≤ 0.01). When treated with rHDL nanoparticles, the probucol-treated group (+) was reduced by 29.3% compared to the untreated group (-) (Figure 37 ○) (*p ≤ 0.05).

[0243] In the case of LN229 cells, the cholesterol efflux (%) in the 24HC-containing rHDL nanoparticle-treated group was reduced by 45.7% in the probucol-treated group (+) compared to the untreated group (-), and when rHDL nanoparticles were treated, it was reduced by 50.0% in the probucol-treated group (+) compared to the untreated group (-) (Fig. 37 △) (LN229; ***p ≤ 0.001). These results indicate that probucol inhibited the cholesterol efflux of rHDL nanoparticles and 24HC-containing rHDL nanoparticles by inhibiting ABCA1, which is involved in cholesterol efflux.

[0244] In conclusion, 24HC-loaded rHDL nanoparticles exhibited ABCA1-mediated cholesterol efflux. These data demonstrate that 24HC loaded in 24HC-loaded rHDL nanoparticles activates LXR and induces cholesterol efflux through the upregulation of ABCA1. Interestingly, rHDL nanoparticles induced cholesterol efflux without increasing ABCA1 mRNA expression. These results support previous literature reporting that ApoE induces cholesterol efflux through ABCA1.

[0245]

[0246] [Example 11]

[0247] Evaluation of the GBM apoptosis effect due to cholesterol depletion when treated with 24HC-containing rHDL nanoparticles.

[0248] To determine whether cholesterol depletion due to intracellular cholesterol efflux inhibits GBM cell proliferation and induces cell death, U87MG and LN229 cells were treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles, and cell viability was evaluated. After culturing each cell for 24 hours, the cells were treated with the nanoparticles of the present invention at 0-50 μg / mL, and cell viability (%) was evaluated after 48 hours of culturing. As shown in Table 4 and Figures 38 and 39, 24HC-containing rHDL nanoparticles exhibited IC50 values ​​of 0.4 and 0.9 μg / mL in U87MG and LN229 cells, respectively, while 24HC alone treatment exhibited IC50 values ​​of 6.7 and 12.8 μg / mL in U87MG and LN229 cells, respectively. 24HC-containing rHDL nanoparticles exhibited an IC50 value approximately 14-fold lower than that of 24HC alone. These results can be interpreted as a consequence of the higher cellular uptake efficiency of 24HC-containing rHDL nanoparticles compared to 24HC, the higher ABCA1 expression, and the higher intracellular cholesterol depletion due to the higher cholesterol efflux, resulting in toxicity. In conclusion, we demonstrated that 24HC-containing rHDL nanoparticles depleted intracellular cholesterol in GBM cells, causing high cytotoxicity.

[0249] Cell Formulation IC50 values ​​(unit: μg / mL) 48 hU87MG rHDL nanoparticles 64.4 24HC 6.7 24HC containing rHDL nanoparticles 0.4LN229 rHDL nanoparticles 48.9 24HC 12.8 24HC containing rHDL nanoparticles 0.9

[0250] [Example 12]

[0251] Confirmation of the incorporation of 24HC-containing rHDL nanoparticles into patient-derived GBM cells

[0252] The 24HC-containing rHDL nanoparticles manufactured according to the manufacturing method of Example 2 were used to confirm nanoparticle uptake into patient-derived GBM cells using the following method. GBM#P1 and GBM#P2 ​​cells were cultured in DMEM / F12 medium supplemented with 1% P / S, 15% FBS, EGF (50 ng / mL), and FGF-10 (50 ng / mL). Each cell was cultured at 37°C in a 5% CO2 atmosphere and 95% relative humidity. The cells were processed and quantified as in Example 8.

[0253] Figure 40 shows the results of the intracellular uptake of Cy5.5-rHDL nanoparticles and Cy5.5-24HC-containing rHDL nanoparticles of the present invention (scale bar is 50 μm). It was confirmed that both Cy5.5-rHDL nanoparticles and Cy5.5-24HC-containing rHDL nanoparticles were taken up into the cytoplasm in the same way as U87MG and LN229. Figure 41 shows the results of quantifying each nanoparticle taken up into GBM#P1 and Figure 42 shows the results of quantifying each nanoparticle taken up into GBM#P2. Based on the results of each intracellular experiment, it was quantitatively confirmed that the rHDL nanoparticles of the present invention were delivered into GBM#P1 and GBM#P2 ​​cells, and that even if 24HC was included in the rHDL nanoparticles, the GBM uptake efficiency was not reduced and the delivery was effective.

[0254]

[0255] [Example 13]

[0256] Changes in LDLR and ABCA1 mRNA expression in patient-derived GBM cells induced by 24HC-containing rHDL nanoparticles

[0257] Changes in LDLR and ABCA1 mRNA expression were confirmed by qPCR after treating GBM#P1 and GBM#P2 ​​cells with 24HC, 24HC-containing rHDL nanoparticles, and rHDL nanoparticles. GBM#P1 and GBM#P2 ​​cells were seeded in 6-well cell culture plates at a density of 0.5 x 10 5Cells were seeded at 10 cells / well and cultured for 24 hours. The cells were cultured under the conditions described in Example 12. GBM#P1 and GBM#P2 ​​cells were treated with 24HC and 24HC-containing rHDL nanoparticles at a concentration of 2 μg / mL of 24HC for 4 hours. In the case of rHDL nanoparticles, the amount of apolipoprotein E3 in the 24HC-containing rHDL nanoparticles was quantified using a BCA assay, and then the same amount of apolipoprotein E3 corresponding to the 24HC treatment concentration was calculated before treating the rHDL nanoparticles.

[0258] When GBM#P1 and GBM#P2 ​​cells were treated with 24HC and 24HC-containing rHDL nanoparticles, the expression level of LDLR mRNA was significantly reduced compared to the control, and statistical significance was observed (Fig. 43). The 24HC-containing rHDL nanoparticle treatment group reduced LDLR mRNA expression by 0.5 times compared to the control group and 1.3 times compared to 24HC (GBM#P1, GBM#P2; ****p ≤ 0.0001). In addition, 24HC-containing rHDL nanoparticles significantly increased ABCA1 mRNA expression compared to the control group. The 24HC-containing rHDL nanoparticle treatment group increased ABCA1 mRNA expression by 5.1 times compared to the control group, 2.1 times compared to 24HC, and 5.7 times compared to rHDL nanoparticles (Fig. 44). In particular, the 24HC-containing rHDL nanoparticle treatment group showed a significant difference compared to the control and 24HC (GBM#P1, GBM#P2; ****p ≤ 0.0001). However, this significance was calculated by integrating the raw data values ​​of the control and experimental groups for GBM#P1 and GBM#P2 ​​cells.

[0259] In patient-derived GBM cells, 24HC-containing rHDL nanoparticles increased ABCA1 mRNA expression compared to 24HC alone, similar to U87MG and LN229 cells. These results indicate that 24HC-containing rHDL nanoparticles comprehensively induce intracellular cholesterol depletion in patient-derived GBM cells.

[0260]

[0261] [Example 14]

[0262] Changes in cholesterol efflux in patient-derived GBM cells induced by 24HC-containing rHDL nanoparticles

[0263] GBM#P1 and GBM#P2 ​​cells were treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles, and the extent of intracellular cholesterol efflux was quantified using a cholesterol efflux kit. GBM#P1 cells were treated with 0.2Х10 5 cells / well, GBM#P2 ​​cells were 0.15Х10 5 Cells were seeded at 1 / well and the experimental method of the cholesterol efflux kit was followed. After culturing the cells to allow the fluorescence-detected cholesterol to enter the cells, each cell was treated with rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles. GBM#P1 and GBM#P2 ​​cells were treated with 24HC and 24HC-containing rHDL nanoparticles at a concentration of 10 μg / mL of 24HC for 24 hours. In the case of rHDL nanoparticles, the amount of apolipoprotein E3 in the 24HC-containing rHDL nanoparticles was quantified using a BCA assay, and then the rHDL nanoparticles were treated after calculating the same amount of apolipoprotein E3 corresponding to the 24HC treatment concentration. After 24 hours, the fluorescence values ​​of cholesterol effluxed into the extracellular and intracellular cholesterol were measured, and the cholesterol efflux rate (%) was calculated by calculating the value of the effluxed extracellular cholesterol in each treatment group compared to the intracellular cholesterol in the control group.

[0264] When the nanoparticles of the present invention were treated on GBM#P1 and GBM#P2, both the rHDL nanoparticle treatment group and the 24HC-containing rHDL nanoparticle treatment group showed a higher cholesterol efflux (%) compared to 24HC, and the 24HC-containing rHDL nanoparticle treatment group effluxed 4.4 times more cholesterol compared to 24HC (Fig. 45) (GBM#P1, GBM#P2; ***p ≤ 0.001). The fact that the 24HC-containing rHDL nanoparticles showed a higher cholesterol efflux (%) compared to the other treatment groups is thought to be due to the high intracellular delivery effect of the 24HC-containing rHDL nanoparticles as shown in Example 8 and the increased ABCA1 mRNA expression in cells after treatment with the 24HC-containing rHDL nanoparticles as shown in Example 13.

[0265] To determine whether 24HC-containing rHDL nanoparticles induce cholesterol efflux through ABCA1 in patient-derived GBM cells, 40 μM of probucol, an ABCA1 inhibitor, was administered to GBM#P1 and GBM#P2 ​​cells (0.15Х10 5cells / well) for 4 hours, and 24HC-containing rHDL nanoparticles and rHDL nanoparticles were treated for 24 hours, and changes in cholesterol efflux were confirmed using a cholesterol efflux kit. GBM#P1 and GBM#P2 ​​cells were treated with 24HC-containing rHDL nanoparticles at a concentration of 10 μg / mL. It was confirmed that cholesterol efflux was reduced in the nanoparticle-treated group after treatment with probucol, an ABCA1 inhibitor, compared to the group not treated with probucol (Fig. 46). Cholesterol efflux (%) in the 24HC-containing rHDL nanoparticle-treated group was reduced by 34.9% in the probucol-treated group (+) compared to the untreated group (-), and when rHDL nanoparticles were treated, it was reduced by 36.7% in the probucol-treated group (+) compared to the untreated group (-). (GBM#P1, GBM#P2; ****p ≤ 0.0001). However, this significance was calculated by integrating the raw data values ​​of the control and experimental groups for GBM#P1 and GBM#P2 ​​cells.

[0266]

[0267] [Example 15]

[0268] Evaluation of the apoptotic efficacy of patient-derived GBM cells by 24HC-containing rHDL nanoparticles

[0269] To determine whether cholesterol depletion due to intracellular cholesterol efflux inhibits GBM cell proliferation and induces cell death, rHDL nanoparticles, 24HC, and 24HC-containing rHDL nanoparticles were treated to GBM#P1 and GBM#P2, and cell viability was evaluated. After culturing each cell for 24 hours, the nanoparticles of the present invention were treated to the cells at 0-50 μg / mL, and cell viability (%) was evaluated after 48 hours of culturing. As shown in Table 5 and Figures 47 and 48, 24HC-containing rHDL nanoparticles exhibited IC50 values ​​of 2.5 and 1.0 μg / mL in GBM#P1 and GBM#P2 ​​cells, respectively, while 24HC alone treatment exhibited IC50 values ​​of 40.2 and 13.8 μg / mL in GBM#P1 and GBM#P2 ​​cells, respectively. These results can be interpreted as a consequence of the higher cellular uptake efficiency of 24HC-containing rHDL nanoparticles compared to 24HC, the higher ABCA1 expression, and the higher intracellular cholesterol depletion due to the higher cholesterol efflux, resulting in toxicity. In conclusion, we demonstrated that 24HC-containing rHDL nanoparticles depleted intracellular cholesterol in patient-derived GBM cells, resulting in high cytotoxicity.

[0270]

[0271] Cell Formulation IC 50 Values ​​(unit: μg / mL) 48 hGBM#P1 rHDL nanoparticles 37.05 24HC 40.2 24HC containing rHDL nanoparticles 2.5 GBM#P2 ​​rHDL nanoparticles 12.0 24HC 13.8 24HC containing rHDL nanoparticles 1.0

Claims

1. Reconstituted high-density lipoprotein (rHDL) nanoparticles containing phospholipids, cholesterol, and apolipoprotein E.

2. In the first paragraph, the cholesterol is cholesterol, 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 4β-hydroxycholesterol, α-5,6-epoxycholesterol, β-5,6-epoxycholesterol, 24S, 25-epoxycholesterol, 25-epoxycholesterol, 7-hydroxycholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(R)-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 5β-epoxycholesterol, 6β-epoxycholesterol, 7-dehydrocholesterol, (25R)26-hydroxycholesterol, 7α,(25R)26-dihydroxycholesterol, 5β-cholestane-3α,7α,12α,(25R)26-tetrol, 7α,25-dihydroxycholesterol (7α,25-dihydroxycholesterol), 7α,24S-dihydroxycholesterol, 3β,5α,6β-cholestane-3,5,6,26-tetrol, Lanosterol, Desmosterol, 7α-hydroxydesmosterol, (24Z),26S-hydroxydesmosterol, (24E),26S-hydroxydesmosterol, 24S,25-epoxylanosterol, 26(Z)-hydroxydesmosterol, 25-hydroxy-8-dehydrocholesterol, 24-hydroxy-8-dehydrocholesterol, 7-dehydrocholesterol, 8-dehydrocholesterol, (25R)26-hydroxy-8-dehydrocholesterol, 25-hydroxy-7-dehydrocholesterol, 4α-hydroxy-7-dehydrocholesterol, 4β-hydroxy-7-dehydrocholesterol, 7,8-epoxycholesterol, 3α,5β,6α-cholestane-3,6-diol, cholestan-3β, 5α, 6β-triol, Oxy34, Oxy49,A reconstituted high-density lipoprotein (rHDL) nanoparticle characterized by at least one selected from the group consisting of and Oxy133.

3. A reconstructed high-density lipoprotein (rHDL) nanoparticle according to claim 1, characterized in that the cholesterol is 24-hydroxycholesterol (24HC).

4. A reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, characterized in that the nanoparticle further comprises a liver X receptor (LXR) stimulator.

5. A reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 4, wherein the liver X receptor stimulator is at least one selected from the group consisting of T0901317, GW3965, GW6340, DMHCA, LXR-623, WYE-672, and AZ876.

6. A reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, characterized in that the nanoparticle further comprises ShK.

7. A reconstituted high-density lipoprotein (rHDL) nanoparticle characterized in that the molar ratio of apolipoprotein E and cholesterol in the first paragraph is 1:2 to 1:

4.

8. A reconstituted high-density lipoprotein (rHDL) nanoparticle characterized in that the molar ratio of apolipoprotein E and cholesterol in the first paragraph is 1:

3.

9. A reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the apolipoprotein E is apolipoprotein E2, E3, or E2 and E3.

10. A reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, characterized in that it may additionally contain apolipoprotein A1.

11. In the first paragraph, the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), 1,2-Diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1,2-Diicosanoyl-sn-glycero-3-phosphocholine (DEPC), Palmitoyloleoylphosphatidylcholine (POPC), Lysophosphatidylcholine, Dilinoleoylphosphatidylcholine, Distearoylphosphatidylethanolamine (DSPE), Dimyristoylphosphatidylethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), Palmitoyloleoylphosphatidylethanolamine (POPE), Lysophosphatidylethanolamine, N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide)(VL-5), Dioctadecylamidoglyclespermine 4-trifluoroacetic acid (DOGS), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), (1,2-dioleyloxypropyl)-3-dimethylhydroxyethyl ammonium bromide (DORIE), 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N-(3-aminopropyl)-N,N-dimethyl-2,A reconstituted high-density lipoprotein (rHDL) nanoparticle characterized by at least one selected from the group consisting of 3-bis(dodecyloxy)-1-propanammonium bromide (GAP-DLRIE), Nt-butyl-N'-tetradecyl-3-tetradecylaminopropionamidine (diC14-amidine), ethylphosphocholine (Ethyl PC), dimethyldioctadecylammonium bromide (DDAB), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), D-Lin-MC3-DMA (MC3, DLin-MC3-DMA), DLin-KC2-DMA, and DLin-DMA.

12. A reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, characterized in that the diameter is 25 nm or less.

13. In the third paragraph, the nanoparticle is a reconstituted high-density lipoprotein (rHDL) nanoparticle characterized by increasing the expression of ABCA1.

14. In the third paragraph, the nanoparticle is a reconstituted high-density lipoprotein (rHDL) nanoparticle characterized by increasing cholesterol efflux.

15. In the third paragraph, the nanoparticle is a reconstituted high-density lipoprotein (rHDL) nanoparticle characterized by killing cancer cells.

16. In the first paragraph, the reconstructed high-density lipoprotein (rHDL) nanoparticles are characterized in that the nanoparticles enter cells through LDLR.

17. A composition for preventing or treating Alzheimer's disease or cancer, comprising the nanoparticle of clause 3.

18. A composition for preventing or treating cancer, characterized in that the cancer in claim 17 is selected from the group consisting of carcinoma, sarcoma, lymphoma, leukemia, germ cell tumor, brain tumor corresponding to blastoma, cervical cancer, ovarian cancer, prostate cancer, lung cancer, bile duct cancer, kidney cancer, stomach cancer, liver cancer, retinoblastoma, choriocarcinoma, small intestine cancer, colon cancer and rectal cancer, non-small cell lung cancer, gastric adenocarcinoma, acute lymphoblastic leukemia, acute myeloid leukemia, breast cancer, bone sarcoma, bladder cancer, anaplastic astrocytoma, head and neck cancer, pancreatic cancer, and esophageal cancer.

19. A composition for preventing or treating cancer, characterized in that the cancer is a brain tumor in claim 18. A first step of injecting a phospholipid solution into a second inlet located in the center of a microfluidic device including 20.3 inlets and 1 outlet; A second step of manufacturing nanoparticles by injecting apolipoproteins into the first and third inlets located on both sides; and A third step of adding cholesterol to the manufactured nanoparticles is included. A method for preparing reconstituted high-density lipoprotein (rHDL) nanoparticles comprising phospholipids, cholesterol and apolipoprotein.

21. A method for manufacturing reconstructed high-density lipoprotein (rHDL) nanoparticles, characterized in that the microfluidic device in claim 20 has a microcolumn structure.

22. A method for producing reconstituted high-density lipoprotein (rHDL) nanoparticles, characterized in that the method further comprises a step of removing an organic solvent after the second step in the 20th paragraph.

23. A method for producing reconstituted high-density lipoprotein (rHDL) nanoparticles, characterized in that the cholesterol in claim 20 is 24-hydroxycholesterol.

24. A method for producing reconstituted high-density lipoprotein (rHDL) nanoparticles, characterized in that the apolipoprotein in claim 20 is apolipoprotein E.

25. A method for producing reconstituted high-density lipoprotein (rHDL) nanoparticles, characterized in that in claim 24, the apolipoprotein E is apolipoprotein E2, E3, or E2 and E3.

26. In paragraph 20, the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), 1,2-Diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1,2-Diicosanoyl-sn-glycero-3-phosphocholine (DEPC), Palmitoyloleoylphosphatidylcholine (POPC), Lysophosphatidylcholine, Dilinoleoylphosphatidylcholine, Distearoylphosphatidylethanolamine (DSPE), Dimyristoylphosphatidylethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), Palmitoyloleoylphosphatidylethanolamine (POPE), Lysophosphatidylethanolamine, N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide)(VL-5), Dioctadecylamidoglyclespermine 4-trifluoroacetic acid (DOGS), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), (1,2-dioleyloxypropyl)-3-dimethylhydroxyethyl ammonium bromide (DORIE), 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N-(3-aminopropyl)-N,N-dimethyl-2,A method for producing reconstituted high-density lipoprotein (rHDL) nanoparticles, characterized in that at least one is selected from the group consisting of 3-bis(dodecyloxy)-1-propanammonium bromide (GAP-DLRIE), Nt-butyl-N'-tetradecyl-3-tetradecylaminopropionamidine (diC14-amidine), ethylphosphocholine (Ethyl PC), dimethyldioctadecylammonium bromide (DDAB), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), D-Lin-MC3-DMA (MC3, DLin-MC3-DMA), DLin-KC2-DMA, and DLin-DMA.

27. In the 20th paragraph, the cholesterol is cholesterol, 7-ketocholesterol, 7α-hydroxycholesterol, 7β-hydroxycholesterol, 4β-hydroxycholesterol, α-5,6-epoxycholesterol, β-5,6-epoxycholesterol, 24S, 25-epoxycholesterol, 25-epoxycholesterol, 7-hydroxycholesterol, 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(R)-hydroxycholesterol, 25-hydroxycholesterol, 27-hydroxycholesterol, 5β-epoxycholesterol, 6β-epoxycholesterol, 7-dehydrocholesterol, (25R)26-hydroxycholesterol, 7α,(25R)26-dihydroxycholesterol, 5β-cholestane-3α,7α,12α,(25R)26-tetrol, 7α,25-dihydroxycholesterol (7α,25-dihydroxycholesterol), 7α,24S-dihydroxycholesterol, 3β,5α,6β-cholestane-3,5,6,26-tetrol, Lanosterol, Desmosterol, 7α-hydroxydesmosterol, (24Z),26S-hydroxydesmosterol, (24E),26S-hydroxydesmosterol, 24S,25-epoxylanosterol, 26(Z)-hydroxydesmosterol, 25-hydroxy-8-dehydrocholesterol, 24-hydroxy-8-dehydrocholesterol, 7-dehydrocholesterol, 8-dehydrocholesterol, (25R)26-hydroxy-8-dehydrocholesterol, 25-hydroxy-7-dehydrocholesterol, 4α-hydroxy-7-dehydrocholesterol, 4β-hydroxy-7-dehydrocholesterol, 7,8-epoxycholesterol, 3α,5β,6α-cholestane-3,6-diol, cholestan-3β, 5α, 6β-triol, Oxy34, Oxy49,A method for producing reconstituted high-density lipoprotein (rHDL) nanoparticles, characterized in that at least one is selected from the group consisting of and Oxy133.